Mabwell(SH:688062) Ge Long Hui A P P·2026-01-23 08:33Core Viewpoint - Maiwei Biotech (688062.SH) is expected to continue reporting a net loss attributable to shareholders in 2025, with projected losses ranging from -900 million to -994.5 million yuan [1] Financial Performance - The company's operating revenue is anticipated to increase significantly compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISCMEDICINE, INC., along with a notable rise in drug sales revenue [1] - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -905 million and -999.5 million yuan [1] Cost and Investment Factors - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company is maintaining a high level of research and development investment, with multiple innovative drugs currently in critical trial phases [1]